Fact CheckerSign in

NCT06405815Completed

A Radiomic Model for Risk of Local Recurrence and DFS for T3 and T4 Non-small Cell Lung Cancer

Development of a Tumor and Peritumor Radiomics-based Model to Predict the High-risk Surgical Margin and Prognosis of T3 and T4 Non-Small Cell Lung Cancer

Source: ClinicalTrials.gov · Last updated 9 May 2024

Brief summary (registry, in English)

The investigators retrospectively collected the participants with T3 and T4, N0-2, M0 NSCLC patients resected between January 2013 to December 2021 for training and internal validation. The Clinical data, preoperative laboratory results and images were collected. High-risk margins were defined as R1 or R2 surgical margins or local recurrence during follow-up, and the investigators also collected the disease-free survival time. On the Deepwise multi-modal research platform, the images were semi-automatically segmented and expanded outward by 3mm to obtain the peritumor tissue. PyRadiomics was used to extract the radiomic features. LASSO was used to select the features and tumor radiomics model, peritumor model and combined model were built using 5-fold cross-validation. And it was further tested on the independent cohort. Discrimination was assessed by using the C-index and area under the receiver operating characteristic curve (AUC), sensibility, specificity.

Status (registry)
Completed
Study type
Observational
Enrollment
200 (actual)
First submitted
4 May 2024
Start date
1 Jan 2021
Primary completion date
31 Dec 2022
Lead sponsor
Jinling Hospital, China
Diseases
Lung cancer
NCT number
NCT06405815

What you commit to

  • Study type: Observational
  • Participants enrolled: 200
  • From 1 Jan 2021 to the primary completion date, 31 Dec 2022
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • inadequate imaging quality resulted from breathing artifact;
  • without regularly follow-up information on recurrence location and time

Who the study is looking for

  • patients with T3 and T4 stage NSCLC;
  • available preoperative chest CTE within two weeks of surgery

Age in the registry: 18 years to - · Sex: All

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Jinling Hospital
Coordinator of this site? Confirm its status
NanjingChinaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.